Cargando…

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy

AIMS: Childhood-onset hypertrophic cardiomyopathy (HCM) is far less common than adult-onset disease, thus natural history is not well characterized. We aim to describe the characteristics and outcomes of childhood-onset HCM. METHODS AND RESULTS: We performed an observational cohort study of 7677 HCM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marston, Nicholas A, Han, Larry, Olivotto, Iacopo, Day, Sharlene M, Ashley, Euan A, Michels, Michelle, Pereira, Alexandre C, Ingles, Jodie, Semsarian, Christopher, Jacoby, Daniel, Colan, Steven D, Rossano, Joseph W, Wittekind, Samuel G, Ware, James S, Saberi, Sara, Helms, Adam S, Ho, Carolyn Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139852/ https://www.ncbi.nlm.nih.gov/pubmed/33769460 http://dx.doi.org/10.1093/eurheartj/ehab148

Ejemplares similares

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry
por: Marstrand, Peter, et al.
Publicado: (2020)

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation
por: Thompson, Andrea D., et al.
Publicado: (2021)

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
por: Helms, Adam S., et al.
Publicado: (2020)

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
por: Canepa, Marco, et al.
Publicado: (2020)

External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy
por: Norrish, Gabrielle, et al.
Publicado: (2021)

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
por: Ho, Carolyn Y., et al.
Publicado: (2018)

Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry
por: Abou Alaiwi, Sarah, et al.
Publicado: (2023)

Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
por: Coppini, Raffaele, et al.
Publicado: (2014)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy
por: Walsh, Roddy, et al.
Publicado: (2019)

Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers
por: Sweeting, Joanna, et al.
Publicado: (2016)

Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results
por: Smagarinsky, Yana, et al.
Publicado: (2017)

Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy
por: Toepfer, Christopher N., et al.
Publicado: (2020)

Evaluating a custom-designed aid to improve communication of genetic results in families with hypertrophic cardiomyopathy: study protocol for a randomised controlled trial
por: Burns, Charlotte, et al.
Publicado: (2019)

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy
por: Finocchiaro, Gherardo, et al.
Publicado: (2017)

A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy
por: Miron, Anastasia, et al.
Publicado: (2020)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Microvascular Dysfunction in Hypertrophic Cardiomyopathy
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Sex‐Related Differences in Genetic Cardiomyopathies
por: Argirò, Alessia, et al.
Publicado: (2022)

Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment
por: Butters, Alexandra, et al.
Publicado: (2021)

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
por: Bernardini, Andrea, et al.
Publicado: (2023)

Hypertrophic cardiomyopathy: The need for randomized trials
por: Olivotto, Iacopo, et al.
Publicado: (2013)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes
por: Ingles, Jodie, et al.
Publicado: (2019)

Stage-specific therapy for hypertrophic cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2023)

Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
por: Gimeno, Juan R., et al.
Publicado: (2022)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations
por: Fioretti, Chiara, et al.
Publicado: (2020)

Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy
por: Ho, Jennifer E, et al.
Publicado: (2017)

Emerging Medical Treatment for Hypertrophic Cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2021)

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
por: Palandri, Chiara, et al.
Publicado: (2022)

Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy
por: Puckelwartz, Megan J., et al.
Publicado: (2021)

LAMP2 shines a light on cardiomyopathy in an athlete
por: Martin, Sophie, et al.
Publicado: (2017)

Life-long tailoring of management for patients with hypertrophic cardiomyopathy: Awareness and decision-making in changing scenarios
por: Michels, M., et al.
Publicado: (2016)

Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions
por: Zhang, Xiaolei, et al.
Publicado: (2020)

Applying Shared Decision Making to Sports Participation for a Patient With Hypertrophic Cardiomyopathy
por: de Feria, Alejandro E., et al.
Publicado: (2020)

Molecular autopsy in victims of inherited arrhythmias
por: Semsarian, Christopher, et al.
Publicado: (2016)

Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy
por: Farhad, Hoshang, et al.
Publicado: (2017)

Translation of New and Emerging Therapies for Genetic Cardiomyopathies
por: Helms, Adam S., et al.
Publicado: (2021)

Rare desmin variant causing penetrant life-threatening arrhythmic cardiomyopathy
por: Oomen, Ad W.G.J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fgb65p7u1sl0ii203aqsk387qo